Envista Holdings Corp. 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Envista Holdings Corp. (NVST)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Envista is a global provider of dental products and solutions, operating through two segments: Specialty Products & Technologies (implants, orthodontics) and Equipment & Consumables (diagnostics, restorative materials). The company serves over 130 countries, with 53% of sales generated outside the U.S. Key brands include Nobel Biocare, Ormco, DEXIS, and Kerr.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric ($ millions) | 2025 | 2024 | Change |
|---|---|---|---|
| Total Sales | $2,719.5 | $2,510.6 | +8.3% |
| Core Sales Growth (Non-GAAP) | 6.5% | -1.5% | N/A |
| Gross Profit | $1,486.7 | $1,372.7 | +8.3% |
| Gross Margin | 54.7% | 54.7% | Flat |
| Operating Profit | $216.1 | ($1,038.2) | Significant Improvement |
| Net Income | $47.0 | ($1,118.6) | Turnaround to Profit |
| Operating Cash Flow | $275.7 | $336.5 | -18.1% |
| Total Debt (Long-term) | $1,448.3 | $1,278.3 | +13.3% |
| Cash & Equivalents | $1,211.7 | $1,069.1 | +13.4% |
Material Changes vs. Prior Period
- Profitability Recovery: The company returned to profitability in 2025 ($47.0M net income) compared to a significant loss in 2024 ($1,118.6M). This turnaround was primarily driven by the absence of the $1.15 billion goodwill and intangible asset impairment charges recorded in 2024.
- Revenue Growth: Sales increased 8.3% year-over-year, with core sales (excluding acquisitions and currency) growing 6.5%. Growth was driven by higher sales volume and price increases, particularly in North America and Europe.
- Segment Performance:
- Specialty Products & Technologies: Sales rose 8.4% to $1,752.8M; operating profit margin improved to 10.9% from 5.6% in 2024.
- Equipment & Consumables: Sales rose 8.1% to $966.7M; operating profit margin slightly declined to 16.3% from 17.0% due to unfavorable FX and tariffs.
- Debt Structure: The company repaid the $116.3M 2025 Convertible Notes at maturity in June 2025. Outstanding debt increased due to borrowings under the Revolving Credit Facility ($117.5M outstanding at year-end).
- Stock Repurchases: The company repurchased approximately 9.2 million shares for $165.9 million under a $250 million program authorized in February 2025.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Management expects continued growth driven by the expansion of the Spark clear aligner system, new implant product launches, and penetration in emerging markets.
- Strategic priorities remain focused on growth (innovation/commercialization), operations (Envista Business System efficiency), and people (leadership/talent).
- The company anticipates the impact of tariffs and foreign exchange rates to remain a factor, though they aim to offset costs through pricing and supply chain adjustments.
Key Risks & Contingencies:
- Geopolitical & Trade: Ongoing tensions between the U.S. and China, including tariffs and volume-based procurement (VBP) policies in China, pose risks to margins and demand. The Russia-Ukraine conflict and Israel-Hamas war present supply chain and operational risks, though impacts were not material in 2025.
- Regulatory: Extensive regulation by the FDA and EU (MDR) regarding medical devices, data privacy (GDPR, HIPAA), and AI usage in healthcare products.
- Financial: High leverage (approx. $1.5B debt) exposes the company to interest rate volatility. Future impairment charges remain a risk if market capitalization or cash flow forecasts decline.
- Cybersecurity: Risks associated with data breaches and reliance on third-party IT providers.
Investor Verification Checklist
- Impairment History: Verify the sustainability of the 2025 profit turnaround given the $1.15B impairment charge in 2024; assess the risk of future goodwill write-downs.
- Debt Covenants: Confirm compliance with the 4.0x Consolidated Leverage Ratio and 3.0x Interest Coverage Ratio covenants under the Second Amended Credit Agreement.
- China Exposure: Review the impact of China's volume-based procurement (VBP) policies on the ~7% of sales derived from that region.
- Convertible Notes: Monitor the $492.7M 2028 Convertible Notes for potential conversion triggers or dilution risks.
- FX Sensitivity: Assess the impact of a strengthening U.S. dollar on future reported sales, given 53% of revenue is international.